Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
DCM
MCID: DLT002
MIFTS: 78

Dilated Cardiomyopathy (DCM)

Categories: Bone diseases, Cardiovascular diseases, Ear diseases, Genetic diseases, Immune diseases, Muscle diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Dilated Cardiomyopathy

About this section

MalaCards integrated aliases for Dilated Cardiomyopathy:

Name: Dilated Cardiomyopathy 12 74 25 20 58 36 54 15 37 17 32
Familial Dilated Cardiomyopathy 12 74 20 43 58 6 71
Idiopathic Dilation Cardiomyopathy 12 74 71
Idiopathic Dilated Cardiomyopathy 20 6 17
Primary Dilated Cardiomyopathy 12 29 6
Cardiomyopathy, Dilated 44 39 71
Congestive Cardiomyopathy 12 43
Dcm 20 48
Hypokinetic Dilated Cardiomyopathy, Familial 20
Primary Familial Dilated Cardiomyopathy 43
Cardiomyopathy, Familial Idiopathic 71
Familial Idiopathic Cardiomyopathy 43
Cardiomyopathy, Familial Dilated 20
Dilated Cardiomyopathy, Familial 20
Fdc 43

Characteristics:

Orphanet epidemiological data:

58
dilated cardiomyopathy
Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Cardiovascular diseases Immune diseases Neuronal diseases Bone diseases Ear diseases Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 32 33


External Ids:

Disease Ontology 12 DOID:12930
KEGG 36 H00294
MeSH 44 D002311
NCIt 50 C84673
SNOMED-CT 67 74368002
ICD10 32 I42.0
MESH via Orphanet 45 C536231 D002311
ICD10 via Orphanet 33 I42.0
UMLS via Orphanet 72 C0007193 C0340427
UMLS 71 C0007193 C0340427 C1449563 more
Sources

Summaries for Dilated Cardiomyopathy

About this section
KEGG : 36 Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM ("familial" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of "familial" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an "idiopathic" DCM. Current hypotheses regarding causes of "idiopathic" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with "idiopathic" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.

MalaCards based summary : Dilated Cardiomyopathy, also known as familial dilated cardiomyopathy, is related to atrial standstill 1 and familial isolated dilated cardiomyopathy. An important gene associated with Dilated Cardiomyopathy is LMNA (Lamin A/C), and among its related pathways/superpathways are Dilated cardiomyopathy and Cardiac conduction. The drugs Verapamil and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include Heart, and related phenotypes are failure to thrive and congestive heart failure

Disease Ontology : 12 An intrinsic cardiomyopathy that is characterized by an an enlarged heart and damage to the myocardium causing the heart to pump blood inefficiently.

MedlinePlus Genetics : 43 Familial dilated cardiomyopathy is a genetic form of heart disease. It occurs when heart (cardiac) muscle becomes thin and weakened in at least one chamber of the heart, causing the open area of the chamber to become enlarged (dilated). As a result, the heart is unable to pump blood as efficiently as usual. To compensate, the heart attempts to increase the amount of blood being pumped through the heart, leading to further thinning and weakening of the cardiac muscle. Over time, this condition results in heart failure.It usually takes many years for symptoms of familial dilated cardiomyopathy to cause health problems. They typically begin in mid-adulthood, but can occur at any time from infancy to late adulthood. Signs and symptoms of familial dilated cardiomyopathy can include an irregular heartbeat (arrhythmia), shortness of breath (dyspnea), extreme tiredness (fatigue), fainting episodes (syncope), and swelling of the legs and feet. In some cases, the first sign of the disorder is sudden cardiac death. The severity of the condition varies among affected individuals, even in members of the same family.

GARD : 20 Dilated cardiomyopathy (DCM) is a disease of the heart muscle which primarily affects the heart's main pumping chamber, the left ventricle. It is the most common type of cardiomyopathy and typically affects those aged 20 to 60. The left ventricle of affected individuals becomes enlarged (dilated) and cannot pump blood to the body with as much force as a healthy heart can. The heart muscle also has difficulty contracting normally, which can lead to irregular heartbeats (arrhythmia), blood clots, or sudden death. Over time, the heart becomes weaker and heart failure can occur. While the cause of dilated cardiomyopathy is often unknown (idiopathic), some cases are acquired and roughly half are inherited or familial. Also, DCM can be a feature of many genetic syndromes. Familial dilated cardiomyopathy is most often inherited in an autosomal dominant pattern. Familial dilated cardiomyopathy is caused by mutations in several different genes, most commonly in the TTN gene (found in about 20% of cases). DCM treatment may include medication, pacemakers, implantable cardiac defibrillators, or heart transplantation.

Wikipedia : 74 Dilated cardiomyopathy (DCM) is a condition in which the heart becomes enlarged and cannot pump blood... more...

GeneReviews: NBK1309
Sources

Related Diseases for Dilated Cardiomyopathy

About this section

Diseases in the Rare Cardiomyopathy family:

Cardiomyopathy, Dilated, 1a Cardiomyopathy, Dilated, 3b
Cardiomyopathy, Dilated, 1b Cardiomyopathy, Dilated, 1e
Cardiomyopathy, Dilated, 1d Cardiomyopathy, Dilated, 1g
Cardiomyopathy, Dilated, 1h Cardiomyopathy, Dilated, 1i
Cardiomyopathy, Dilated, 1j Cardiomyopathy, Dilated, 1k
Cardiomyopathy, Dilated, 1l Cardiomyopathy, Dilated, 1m
Cardiomyopathy, Dilated, 1o Cardiomyopathy, Dilated, 1p
Cardiomyopathy, Dilated, 1q Cardiomyopathy, Dilated, 1w
Cardiomyopathy, Dilated, 1x Cardiomyopathy, Dilated, 1z
Cardiomyopathy, Dilated, 2a Cardiomyopathy, Dilated, 1bb
Cardiomyopathy, Dilated, 1cc Cardiomyopathy, Dilated, 1dd
Cardiomyopathy, Dilated, 1ee Cardiomyopathy, Dilated, 1ff
Cardiomyopathy, Dilated, 1r Cardiomyopathy, Dilated, 1gg
Cardiomyopathy, Dilated, 1u Cardiomyopathy, Dilated, 1v
Cardiomyopathy, Dilated, 1hh Cardiomyopathy, Dilated, 2b
Cardiomyopathy, Dilated, 1ii Cardiomyopathy, Dilated, 1jj
Cardiomyopathy, Dilated, 1kk Cardiomyopathy, Dilated, 1nn
Cardiomyopathy, Dilated, 2c Autoimmune Cardiomyopathy
Dilated Cardiomyopathy 1t Dilated Cardiomyopathy
Lmna-Related Dilated Cardiomyopathy Cardiomyopathy Due to Anthracyclines

Diseases related to Dilated Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 967)
# Related Disease Score Top Affiliating Genes
1 atrial standstill 1 35.1 TTN-AS1 TPM1 TNNT2 TNNI3 TAZ SCN5A
2 familial isolated dilated cardiomyopathy 34.6 TTN-AS1 TPM1 TNNT2 TNNI3 TAZ SCN5A
3 cardiomyopathy, dilated, 1e 34.4 TTN-AS1 TPM1 SCN5A RBM20 MYH7 LMNA
4 cardiomyopathy, dilated, 1b 34.2 TTN-AS1 TNNT2 SCN5A RBM20 MYH7 MYH6
5 cardiomyopathy, dilated, 1a 34.2 TTN-AS1 RBM20 MYBPC3 LMNA DSP BAG3
6 hypertrophic cardiomyopathy 34.0 TPM1 TNNT2 TNNI3 TAZ SCN5A RBM20
7 cardiomyopathy, dilated, 1h 33.9 TTN-AS1 RBM20 MYBPC3 LMNA DSP DES
8 myopathy 33.5 TTN-AS1 TPM1 TNNT2 TNNI3 TAZ MYH7
9 lmna-related dilated cardiomyopathy 33.5 TTN-AS1 RBM20 MYBPC3 LMNA DSP BAG3
10 left ventricular noncompaction 33.5 TTN-AS1 TPM1 TNNT2 TNNI3 TAZ SCN5A
11 heart disease 33.5 TPM1 TNNT2 TNNI3 TAZ SCN5A MYH7
12 barth syndrome 33.4 TNNT2 TAZ MYH7 MYH6 MYBPC3
13 myocarditis 33.4 TNNI3 MYH6 DSP DMD
14 cardiomyopathy, dilated, 1ee 33.3 TPM1 MYH6
15 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 33.3 SCN5A MYH7 DSP
16 cardiomyopathy, dilated, 3b 33.3 TAZ DMD
17 myopathy, myofibrillar, 1 33.3 LMNA FLNC DMD DES BAG3
18 cardiomyopathy, dilated, 1dd 33.3 TNNT2 RBM20
19 congestive heart failure 33.2 TNNT2 TNNI3 SCN5A MYH7 MYH6 ACTN2
20 danon disease 33.2 MYH7 MYH6 MYBPC3 LAMP2 CSRP3
21 muscular dystrophy 33.2 TTN-AS1 TNNT2 MYH7 LMNA FLNC DMD
22 cardiac conduction defect 33.0 SCN5A MYH7 MYH6 MYBPC3 LMNA DSP
23 mitral valve insufficiency 32.9 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
24 congenital fiber-type disproportion 32.8 MYH7 MYH6 LMNA DMD
25 arrhythmogenic right ventricular cardiomyopathy 32.8 SCN5A RBM20 MYH7 MYH6 LMNA FLNC
26 left bundle branch hemiblock 32.7 TNNT2 TNNI3 SCN5A LMNA DSP
27 restrictive cardiomyopathy 32.7 TTN-AS1 TPM1 TNNT2 TNNI3 MYH7 MYH6
28 cardiomyopathy, familial hypertrophic, 1 32.7 TPM1 TNNT2 TNNI3 SCN5A MYH7 MYH6
29 atrioventricular block 32.7 TTN-AS1 TNNI3 SCN5A MYH7 LMNA DES
30 lipoprotein quantitative trait locus 32.6 TNNT2 TNNI3 SCN5A MYH7 MYH6 MYBPC3
31 brugada syndrome 32.5 TTN-AS1 TPM1 TNNT2 TNNI3 SCN5A RBM20
32 long qt syndrome 32.5 TTN-AS1 SCN5A RBM20 MYH7 MYH6 MYBPC3
33 ventricular fibrillation, paroxysmal familial, 1 32.4 TNNT2 SCN5A DSP
34 cardiac arrest 32.3 TNNT2 TNNI3 SCN5A MYH7 MYBPC3 DSP
35 syncope 32.3 TNNT2 SCN5A ACTN2
36 progressive familial heart block, type ia 32.3 SCN5A DSP
37 wolff-parkinson-white syndrome 32.2 TTN-AS1 TNNT2 TNNI3 SCN5A MYH7 MYH6
38 neuromuscular disease 32.2 TTN-AS1 SCN5A MYH7 MYH6 LMNA DMD
39 muscular dystrophy, duchenne type 32.1 TNNT2 TNNI3 DMD DES
40 endocardial fibroelastosis 32.1 TAZ MYH7 CSRP3 ACTN2
41 atrial fibrillation 32.0 SCN5A MYH7 MYBPC3 LMNA
42 atrial heart septal defect 31.9 TNNT2 TNNI3 SCN5A MYH7 MYH6 DMD
43 tetralogy of fallot 31.8 TPM1 TNNT2 TNNI3 SCN5A MYH6 ACTN2
44 emery-dreifuss muscular dystrophy 31.8 LMNA DMD DES
45 myofibrillar myopathy 31.7 MYH7 MYH6 LMNA FLNC DMD DES
46 sick sinus syndrome 31.7 SCN5A MYH6 LMNA
47 muscular dystrophy, congenital, lmna-related 31.6 TTN-AS1 MYH7 MYH6 LMNA DMD
48 aortic valve disease 2 31.6 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
49 laminopathy 31.5 SCN5A LMNA
50 cardiomyopathy, familial hypertrophic, 4 31.5 TPM1 TNNT2 MYH7 MYBPC3 DMD

Graphical network of the top 20 diseases related to Dilated Cardiomyopathy:



Diseases related to Dilated Cardiomyopathy
Sources

Symptoms & Phenotypes for Dilated Cardiomyopathy

About this section

Human phenotypes related to Dilated Cardiomyopathy:

58 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 failure to thrive 58 Frequent (79-30%)
2 congestive heart failure 58 Frequent (79-30%)
3 abnormal levels of creatine kinase in blood 58 Occasional (29-5%)
4 mitral regurgitation 58 Occasional (29-5%)
5 left ventricular hypertrophy 58 Very frequent (99-80%)
6 dyspnea 58 Frequent (79-30%)
7 arrhythmia 58 Frequent (79-30%)
8 cough 58 Occasional (29-5%)
9 atrial fibrillation 58 Frequent (79-30%)
10 reduced ejection fraction 58 Frequent (79-30%)
11 coronary artery atherosclerosis 58 Excluded (0%)
12 palpitations 58 Occasional (29-5%)
13 ventricular arrhythmia 58 Occasional (29-5%)
14 elevated pulmonary artery pressure 58 Occasional (29-5%)
15 right ventricular dilatation 58 Frequent (79-30%)
16 left ventricular systolic dysfunction 58 Very frequent (99-80%)
17 left bundle branch block 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Dilated Cardiomyopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.3 BAG3 CSRP3 DES DMD DSP FLNC
2 growth/size/body region MP:0005378 10.13 BAG3 CSRP3 DMD DSP FLNC LAMP2
3 homeostasis/metabolism MP:0005376 10.07 BAG3 CSRP3 DES DMD FLNC LAMP2
4 mortality/aging MP:0010768 10.03 BAG3 CSRP3 DES DMD DSP FLNC
5 muscle MP:0005369 9.86 BAG3 CSRP3 DES DMD DSP FLNC
6 respiratory system MP:0005388 9.23 BAG3 CSRP3 DMD FLNC LMNA MYH6
Sources

Drugs & Therapeutics for Dilated Cardiomyopathy

About this section

Drugs for Dilated Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verapamil Approved Phase 4 52-53-9 2520
2
Enalaprilat Approved Phase 4 76420-72-9 6917719
3
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
4
Doxazosin Approved Phase 4 74191-85-8 3157
5
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
6
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
7
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
8
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
9
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
10
Digoxin Approved Phase 4 20830-75-5 30322 2724385
11
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
12
Adenosine Approved, Investigational Phase 4 58-61-7 60961
13
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
14
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
15 Angiotensin-Converting Enzyme Inhibitors Phase 4
16 HIV Protease Inhibitors Phase 4
17
protease inhibitors Phase 4
18 Hormones Phase 4
19 Calcium, Dietary Phase 4
20 calcium channel blockers Phase 4
21 Protective Agents Phase 4
22 Antioxidants Phase 4
23 Adrenergic alpha-1 Receptor Antagonists Phase 4
24 Adrenergic alpha-Antagonists Phase 4
25 Angiotensinogen Phase 4
26 Angiotensin II Type 1 Receptor Blockers Phase 4
27 Angiotensin Receptor Antagonists Phase 4
28 Giapreza Phase 4
29 Diuretics, Potassium Sparing Phase 4
30 Sodium Channel Blockers Phase 4
31 Trace Elements Phase 4
32 Vitamins Phase 4
33 Ubiquinone Phase 4
34 Nutrients Phase 4
35 Micronutrients Phase 4
36 diuretics Phase 4
37 Mineralocorticoid Receptor Antagonists Phase 4
38 Mineralocorticoids Phase 4
39 Hormone Antagonists Phase 4
40 Cytochrome P-450 CYP3A Inhibitors Phase 4
41 Cytochrome P-450 Enzyme Inhibitors Phase 4
42 Potassium Channel Blockers Phase 4
43 Vasodilator Agents Phase 4
44 Analgesics Phase 4
45 Neurotransmitter Agents Phase 4
46 Anti-Arrhythmia Agents Phase 4
47
Calcium Nutraceutical Phase 4 7440-70-2 271
48
Ethanol Approved Phase 3 64-17-5 702
49
Coal tar Approved Phase 3 8007-45-2
50
Bisoprolol Approved Phase 2, Phase 3 66722-44-9 2405

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
2 A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study Unknown status NCT00541268 Phase 4
3 Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart Completed NCT01798992 Phase 4 Carvedilol;Metoprolol succinate;Metoprolol succinate + doxazosin
4 Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
5 A Multi-center, Randomized, Double, Placebo-controlled, Parallel Group Study of Improving Heart Function and Immunoregulation Effects of Qiliqiangxin Capsule in Patients With Dilated Cardiomyopathy Completed NCT01293903 Phase 4 Qiliqiangxin capsule;Placebo
6 Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial Completed NCT02115581 Phase 4 Coenzyme Q10;Placebo
7 Effect of Aldosterone on Energy Starvation in Heart Failure Completed NCT00574119 Phase 4 spironolactone
8 Phase 4. Study of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. Completed NCT01181414 Phase 4 Beta blocker/digoxine/amiodarone
9 A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
10 Pulse Reduction On Beta-blocker and Ivabradine Therapy Recruiting NCT02973594 Phase 4 Ivabradine;Placebo
11 Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Terminated NCT03249272 Phase 4 Regadenoson;Adenosine
12 Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside (RES-HF) Unknown status NCT01914081 Phase 3
13 Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Unknown status NCT02652728 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
14 Impact of Continues Positive Airway Pressure Treatment in Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea (RIDA) Unknown status NCT02989181 Phase 3
15 Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Unknown status NCT02654678 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
16 The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection Completed NCT00741156 Phase 3 Enalaprilat
17 Honey Supplementation in Children With Idiopathic Dilated Cardiomyopathy: A Randomized Controlled Study Completed NCT02987322 Phase 2, Phase 3
18 Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Dilated Cardiomyopathy Completed NCT00333827 Phase 3 optimal therapy for cardiaca failure
19 Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy: Randomized Clinical Trial Completed NCT00743639 Phase 2, Phase 3
20 A Randomized, Controlled Study to Evaluate the Safety and Cardiovascular Effects of Algisyl-LVRâ„¢ as a Method of Left Ventricular Augmentation in Patients With Dilated Cardiomyopathy (AUGMENT-HF) Completed NCT01311791 Phase 2, Phase 3 Standard medical therapy
21 Effects of n-3 Polyunsaturated Fatty Acids (PUFAs) on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy Completed NCT01223703 Phase 3 n-3 PUFAs;Placebo
22 Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy Completed NCT02248532 Phase 2, Phase 3
23 A Phase III Study of the Effect of Rosuvastatin on Left Ventricular Remodeling and Inflammatory Markers in Heart Failure Completed NCT00505154 Phase 3 Rosuvastatin;placebo
24 A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation Recruiting NCT03439514 Phase 3 ARRY-371797
25 Bisoprolol for Early Cardiomyopathy in Duchenne Muscular Dystrophy: a Randomized, Controlled Trial Recruiting NCT03779646 Phase 2, Phase 3 Bisoprolol Fumarate
26 Preventive Effect of ACE Inhibitor Perindopril)on the Onset or Progression of Left Ventricular Dysfoction in Subjects at a Preclinical Stage From Families With Dilated Cardiomyopathy Terminated NCT01583114 Phase 3 perindopril;placebo
27 Effectiveness of Mental Stress Reduction in Defibrillator Patients Terminated NCT00624520 Phase 3
28 Phase I/II Randomized Clinical Trial to Assess the Safety and Feasibility of Transendocardial Injection of Bone Marrow Autologous Mesenchymal Stem Cells in Patients With Idiopathic Dilated Cardiomyopathy. Unknown status NCT01957826 Phase 1, Phase 2
29 Effects of Intramuscular Injection of Umbilical Cord Mesenchymal Stem Cell on the Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy Unknown status NCT01219452 Phase 1, Phase 2
30 Effects of Ranolazine on Myocardial Perfusion in Patients With Dilated Cardiomyopathy Unknown status NCT02133911 Phase 2 Ranolazine
31 A Controlled Open Label Phase II Study Assessing the Efficacy of Intracoronary Autologous Mesenchymal Stem Cells in Patients With Ischemic Dilated Cardiomyopathy Unknown status NCT01720888 Phase 2
32 Left Cardiac Sympathetic Denervation (LCSD) for Cardiomyopathy Feasibility Pilot Study Unknown status NCT03071653 Phase 2
33 Randomised Controlled Trial to Compare the Effects of G-CSF (Granocyteâ„¢) and Autologous Bone Marrow Progenitor Cells on Quality of Life and Left Ventricular Function in Patients With Idiopathic Dilated Cardiomyopathy Completed NCT01302171 Phase 2 granulocyte colony stimulating factor (GCSF)
34 Metabolic Manipulation in Chronic Heart Failure Completed NCT00841139 Phase 2 Perhexiline;Placebo
35 Intracoronary Transplantation of Autologous Bone Marrow Derived Mononuclear Cells (MNC) in Idiopathic Dilated Cardiomyopathy in Pediatric Patients: Clinical Trial Phase I/II Completed NCT02256501 Phase 1, Phase 2
36 Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy in Dilated Cardiomyopathy - Technique and Early Results Completed NCT00615394 Phase 1, Phase 2
37 SYM-08-001: A Pilot Study to Evaluate the Safety and Feasibility of Algisyl-LVRâ„¢ as a Method of Left Ventricular Restoration in Patients With Dilated Cardiomyopathy Undergoing Open-heart Surgery Completed NCT00847964 Phase 2
38 Catheter-based Transendocardial Delivery of Autologous Bone Marrow-Derived Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy Completed NCT01020968 Phase 2
39 Intramyocardial Delivery of Autologous Bone Marrow Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy Completed NCT00765518 Phase 2
40 Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Completed NCT01350310 Phase 2
41 A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Dilated Cardiomyopathy. Completed NCT01392625 Phase 1, Phase 2
42 A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy Completed NCT02057341 Phase 2 ARRY-371797, p38 inhibitor; oral
43 Effects of Intracoronary Infusion of Bone Marrow-derived Progenitor Cells on Myocardial Regeneration in Patients With Non-ischemic Dilated Cardiomyopathy. Completed NCT00629096 Phase 2
44 The Effects of Autologous Intracoronary Stem Cell Transplantation In Patients With End-Stage Dilated Cardiomyopathy Completed NCT00629018 Phase 2 Bone Marrow Stimulation
45 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Transendocardial Injection of Ixmyelocel-T in Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM). Completed NCT01670981 Phase 2
46 Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction Completed NCT03447990 Phase 1, Phase 2 MYK-491;Placebo
47 Phase 1 Randomized-Double Blind Clinical Trial of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Transplantation in Heart Failure on Patients With Cardiopathy in Dilated Stage, of Different Etiology Completed NCT01739777 Phase 1, Phase 2
48 Transplantation Of Progenitor Cells And Recovery Of Left Ventricular Function In Patients With Nonischemic Dilatative Cardiomyopathy Completed NCT00284713 Phase 1, Phase 2
49 COR-1, an Anti-Beta1 Receptor Antibody Cyclopeptide in Heart Failure: a Phase II, Multicentre, Randomised, Double-Blind and Placebo-Controlled Study With Parallel Groups Completed NCT01391507 Phase 2 0.9 % sodium chloride;COR-1;Standard therapy for heart failure
50 Assessment of Metabolic Function and Perfusion Using Positron Emission Tomography: An Analysis of Patients With Congestive Cardiomyopathy Before and After Beta-Blockers Completed NCT00001402 Phase 2

Search NIH Clinical Center for Dilated Cardiomyopathy

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Inamrinone
inamrinone lactate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Dilated Cardiomyopathy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Dilated Cardiomyopathy:
Autologous bone marrow-derived stem cells for treatment of dilated cardiomyopathy
Bone marrow-derived hematopoietic stem cells for treatment of pediatric dilated cardiomyopathy
Bone marrow-derived mesenchymal stem cells for treatment of heart diseases
Bone marrow-derived mononuclear cells for myocardial infarction
Enriched bone marrow-derived progenitor cells for heart diseases
Ixmyelocel-T, mesenchymal stem cells and monocytes for dilated cardiomyopathy
Peripheral blood-derived CD34+ stem cells for treatment of dilated cardiomyopathy
Umbilical cord-derived mesenchymal stem cells for treatment of dilated cardiomyopathy
Embryonic/Adult Cultured Cells Related to Dilated Cardiomyopathy:
Bone marrow-derived mononuclear cells
Bone marrow-derived hematopoietic stem cells (family)
Bone marrow-derived mesenchymal stem cells PMIDs: 22940024
Bone marrow-derived mononuclear cells PMIDs: 22834565
Bone marrow-derived mononuclear cells PMIDs: 22834565
Bone marrow-derived progenitor cells PMIDs: 16990385 22651868 16990384 18794392 22936827 23362308
Bone marrow-derived mesenchymal stem cells and monocytes (Ixmyelocel-T) PMIDs: 22453769 22776246
Peripheral blood-derived CD34+ cells PMIDs: 23065358
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: cardiomyopathy, dilated

Sources

Genetic Tests for Dilated Cardiomyopathy

About this section

Genetic tests related to Dilated Cardiomyopathy:

# Genetic test Affiliating Genes
1 Primary Dilated Cardiomyopathy 29 ABCC9 ACTC1 ACTN2 ANKRD1 BAG3 CSRP3 DES DSG2 EYA4 FKTN LDB3 LMNA MYBPC3 MYH6 NEXN PLN PSEN1 PSEN2 RBM20 SGCD TAZ TCAP TMPO TNNT2 TPM1 TTN VCL
Sources

Anatomical Context for Dilated Cardiomyopathy

About this section

MalaCards organs/tissues related to Dilated Cardiomyopathy:

40
Heart, Bone Marrow, Endothelial, Bone, Skeletal Muscle, Brain, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Dilated Cardiomyopathy:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Left Ventricle Cardiomyocytes Affected by disease, potential therapeutic candidate
2 Heart Myocardium Cardiomyocytes Affected by disease
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
4 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
Sources

Publications for Dilated Cardiomyopathy

About this section

Articles related to Dilated Cardiomyopathy:

(show top 50) (show all 17078)
# Title Authors PMID Year
1
Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. 6 25 61
19412328 2008
2
Clinical and functional characterization of TNNT2 mutations identified in patients with dilated cardiomyopathy. 54 6 61
20031601 2009
3
Prevalence of desmin mutations in dilated cardiomyopathy. 61 6 54
17325244 2007
4
Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. 61 54 6
12920062 2003
5
Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. 61 54 6
12628721 2003
6
Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. 54 6 61
10580070 1999
7
Lamin A/C and emerin regulate MKL1-SRF activity by modulating actin dynamics. 6 61
23644458 2013
8
A new c.1621 C > G, p.R541G lamin A/C mutation in a family with DCM and regional wall motion abnormalities (akinesis/dyskinesis): genotype-phenotype correlation. 6 61
21085127 2011
9
Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. 61 6
18349139 2008
10
Loss of desmoplakin isoform I causes early onset cardiomyopathy and heart failure in a Naxos-like syndrome. 61 6
16467215 2006
11
Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. 6 61
15972724 2005
12
Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy. 6 61
12196663 2002
13
Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy. 61 6
11684629 2001
14
Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. 61 6
10662742 2000
15
Multigenic Disease and Bilineal Inheritance in Dilated Cardiomyopathy Is Illustrated in Nonsegregating LMNA Pedigrees. 61 25
30012837 2018
16
The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy. 61 25
26518443 2015
17
A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia. 61 25
25852082 2015
18
Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. 25 61
25589632 2015
19
The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. 25 61
24503780 2014
20
Mitochondrial EFTs defects in juvenile-onset Leigh disease, ataxia, neuropathy, and optic atrophy. 6
25037205 2014
21
Dilated cardiomyopathy: the complexity of a diverse genetic architecture. 61 25
23900355 2013
22
Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. 25 61
23418287 2013
23
Truncations of titin causing dilated cardiomyopathy. 61 25
22335739 2012
24
Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. 61 25
21492761 2011
25
Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. 61 25
20864896 2010
26
Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy. 61 47
20488170 2010
27
Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. 25 61
20458009 2010
28
Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. 61 25
20458010 2010
29
The genetics of dilated cardiomyopathy. 61 25
20186049 2010
30
Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. 25 61
20215591 2010
31
Use of genetics in the clinical evaluation of cardiomyopathy. 61 25
19996403 2009
32
Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. 25 61
19808347 2009
33
Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. 25 61
19095136 2008
34
Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660). 6
17250669 2007
35
A homozygous mutation in the lamin A/C gene associated with a novel syndrome of arthropathy, tendinous calcinosis, and progeroid features. 6
16278265 2006
36
Dilated cardiomyopathy presenting during fetal life. 61 25
16014190 2005
37
Clinical and genetic issues in familial dilated cardiomyopathy. 25 61
15808750 2005
38
Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). 25
29904160 2018
39
Use and interpretation of genetic tests in cardiovascular genetics. 25
20937756 2010
40
Connexin 43 remodeling induced by LMNA gene mutation Glu82Lys in familial dilated cardiomyopathy with atrial ventricular block. 54 61
20497714 2010
41
Heart failure-associated changes in RNA splicing of sarcomere genes. 54 61
20124440 2010
42
The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy. 61 54
20171888 2010
43
Familial dilated cardiomyopathy secondary to dystrophin splice site mutation. 61 54
20206892 2010
44
Dilated cardiomyopathy alters the expression patterns of CAR and other adenoviral receptors in human heart. 61 54
19957088 2010
45
A novel LMNA mutation (R189W) in familial dilated cardiomyopathy: evidence for a 'hot spot' region at exon 3: a case report. 54 61
20307303 2010
46
Identification of a new lamin A/C mutation in a Chinese family affected with atrioventricular block as the prominent phenotype. 54 61
20155465 2010
47
Morphological analysis of 13 LMNA variants identified in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. 61 54
20160190 2010
48
Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology and pathophysiology. 54 61
19744495 2010
49
Prognostic value of tissue Doppler right ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic Peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 61 54
20102927 2010
50
Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. 54 61
18778861 2010
Sources

Variations for Dilated Cardiomyopathy

About this section

ClinVar genetic disease variations for Dilated Cardiomyopathy:

6 (show top 50) (show all 1818)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TAZ NM_000116.5(TAZ):c.718G>C (p.Gly240Arg) SNV Pathogenic 42266 rs387907218 X:153649015-153649015 X:154420676-154420676
2 TTN-AS1 NM_001267550.2(TTN):c.66618C>A (p.Cys22206Ter) SNV Pathogenic 47237 rs397517664 2:179446377-179446377 2:178581650-178581650
3 LMNA NM_170707.4(LMNA):c.348dup (p.Lys117fs) Duplication Pathogenic 48061 rs267607646 1:156085056-156085057 1:156115265-156115266
4 LMNA NM_170707.4(LMNA):c.958del (p.Leu320fs) Deletion Pathogenic 48095 rs397517915 1:156105713-156105713 1:156135922-156135922
5 LMNA NM_170707.4(LMNA):c.244G>A (p.Glu82Lys) SNV Pathogenic 66882 rs59270054 1:156084953-156084953 1:156115162-156115162
6 LMNA NM_170707.4(LMNA):c.1086del (p.Leu363fs) Deletion Pathogenic 155806 rs58389804 1:156105840-156105840 1:156136049-156136049
7 LMNA NM_170707.4(LMNA):c.710T>C (p.Phe237Ser) SNV Pathogenic 180404 rs730880132 1:156104666-156104666 1:156134875-156134875
8 TTN-AS1 NM_001267550.2(TTN):c.71980_71986delinsTA (p.Ala23994_Glu23996delinsTer) Indel Pathogenic 202465 rs794729338 2:179438873-179438879 2:178574146-178574152
9 TTN-AS1 NM_001267550.2(TTN):c.86363G>A (p.Trp28788Ter) SNV Pathogenic 419359 rs1064793814 2:179424496-179424496 2:178559769-178559769
10 RBM20 NM_001134363.3(RBM20):c.1901G>T (p.Arg634Leu) SNV Pathogenic 689585 rs267607001 10:112572056-112572056 10:110812298-110812298
11 TNNI3 NM_000363.5(TNNI3):c.24+2T>A SNV Pathogenic 691809 rs777702465 19:55668662-55668662 19:55157294-55157294
12 TTN-AS1 NM_001267550.2(TTN):c.81341dup (p.Asn27115fs) Duplication Pathogenic 689590 rs1575663327 2:179429517-179429518 2:178564790-178564791
13 PPP1R13L NM_006663.4(PPP1R13L):c.736_764del (p.Pro246fs) Deletion Pathogenic 974805 19:45899643-45899671 19:45396385-45396413
14 CSRP3 NM_003476.5(CSRP3):c.420G>C (p.Trp140Cys) SNV Pathogenic 585278 rs1565050320 11:19206587-19206587 11:19185040-19185040
15 LMNA NM_170707.4(LMNA):c.711_729delinsCC (p.Glu238fs) Indel Pathogenic 691647 rs1572359848 1:156104667-156104685 1:156134876-156134894
16 TTN-AS1 NM_001267550.2(TTN):c.91034G>A (p.Trp30345Ter) SNV Pathogenic 691676 rs1575512482 2:179416593-179416593 2:178551866-178551866
17 TTN-AS1 NM_001267550.2(TTN):c.64038T>G (p.Tyr21346Ter) SNV Pathogenic 691688 rs1161735211 2:179451900-179451900 2:178587173-178587173
18 TTN-AS1 NM_001267550.2(TTN):c.58838del (p.Tyr19613fs) Deletion Pathogenic 691690 rs1576141328 2:179458097-179458097 2:178593370-178593370
19 RAF1 NM_001354689.3(RAF1):c.1982C>T (p.Thr661Met) SNV Pathogenic 142298 rs587777587 3:12626038-12626038 3:12584539-12584539
20 LMNA NM_170707.4(LMNA):c.799T>C (p.Tyr267His) SNV Pathogenic 48084 rs267607593 1:156104755-156104755 1:156134964-156134964
21 LMNA NM_170707.4(LMNA):c.961C>T (p.Arg321Ter) SNV Pathogenic 48096 rs267607554 1:156105716-156105716 1:156135925-156135925
22 CSRP3 NM_003476.5(CSRP3):c.233G>T (p.Gly78Val) SNV Pathogenic 518500 rs963128995 11:19209731-19209731 11:19188184-19188184
23 DMD NM_004006.2(DMD):c.4838G>A (p.Trp1613Ter) SNV Pathogenic 523468 rs1557315928 X:32398634-32398634 X:32380517-32380517
24 LMNA NM_170707.4(LMNA):c.16C>T (p.Gln6Ter) SNV Pathogenic 14477 rs61046466 1:156084725-156084725 1:156114934-156114934
25 ATAD3A GRCh37/hg19 1p36.33-36.31(chr1:834101-6076140) copy number loss Pathogenic 523269 1:834101-6076140
26 TTN-AS1 NM_001267550.2(TTN):c.51581G>A (p.Trp17194Ter) SNV Pathogenic 520481 rs1553692290 2:179474569-179474569 2:178609842-178609842
27 LMNA NM_170707.4(LMNA):c.1494G>A (p.Trp498Ter) SNV Pathogenic 520447 rs57730570 1:156106909-156106909 1:156137118-156137118
28 MYH6 NM_002471.3(MYH6):c.735T>G (p.Phe245Leu) SNV Pathogenic 520533 rs1263987728 14:23873505-23873505 14:23404296-23404296
29 TTN-AS1 NM_001267550.2(TTN):c.90706G>T (p.Glu30236Ter) SNV Pathogenic 520476 rs974510652 2:179416921-179416921 2:178552194-178552194
30 TTN-AS1 NM_001267550.2(TTN):c.72663del (p.Pro24223fs) Deletion Pathogenic 684838 rs1575775337 2:179438196-179438196 2:178573469-178573469
31 TTN-AS1 NM_001267550.2(TTN):c.51654C>G (p.Tyr17218Ter) SNV Pathogenic 429894 rs1131691655 2:179474496-179474496 2:178609769-178609769
32 LMNA NM_170707.4(LMNA):c.254T>G (p.Leu85Arg) SNV Pathogenic 14480 rs28933090 1:156084963-156084963 1:156115172-156115172
33 LMNA NM_170707.4(LMNA):c.585C>G (p.Asn195Lys) SNV Pathogenic 14483 rs28933091 1:156104265-156104265 1:156134474-156134474
34 LMNA NM_170707.4(LMNA):c.608A>G (p.Glu203Gly) SNV Pathogenic 14484 rs28933092 1:156104288-156104288 1:156134497-156134497
35 LMNA NM_170707.4(LMNA):c.1698+13C>A SNV Pathogenic 14485 rs80338938 1:156107547-156107547 1:156137756-156137756
36 LMNA NM_005572.3(LMNA):c.959delT (p.Arg321Glufs) Deletion Pathogenic 14491 rs56771886 1:156105714-156105714 1:156135923-156135923
37 LMNA NM_170707.4(LMNA):c.481G>A (p.Glu161Lys) SNV Pathogenic 14504 rs28933093 1:156100532-156100532 1:156130741-156130741
38 LMNA NM_170707.4(LMNA):c.1621C>G (p.Arg541Gly) SNV Pathogenic 29775 rs56984562 1:156107457-156107457 1:156137666-156137666
39 TTN-AS1 NM_001267550.2(TTN):c.85295del (p.Leu28432fs) Deletion Pathogenic 684873 rs1575616801 2:179425564-179425564 2:178560837-178560837
40 MYH7 NM_000257.4(MYH7):c.1106G>A (p.Arg369Gln) SNV Pathogenic 42822 rs397516089 14:23899016-23899016 14:23429807-23429807
41 TPM1 NM_001018005.2(TPM1):c.688G>A (p.Asp230Asn) SNV Pathogenic 31884 rs199476317 15:63354462-63354462 15:63062263-63062263
42 TNNT2 NM_001276345.2(TNNT2):c.422G>A (p.Arg141Gln) SNV Pathogenic 43637 rs397516464 1:201333493-201333493 1:201364365-201364365
43 RBM20 NM_001134363.3(RBM20):c.2737G>A (p.Glu913Lys) SNV Pathogenic 43998 rs397516607 10:112581114-112581114 10:110821356-110821356
44 DES NM_001927.4(DES):c.38C>T (p.Ser13Phe) SNV Pathogenic 44260 rs62636495 2:220283222-220283222 2:219418500-219418500
45 CEP85L NM_002667.5(PLN):c.37_39AGA[1] (p.Arg14del) Microsatellite Pathogenic 44580 rs397516784 6:118880120-118880122 6:118558957-118558959
46 BAG3 NM_004281.4(BAG3):c.1363G>A (p.Glu455Lys) SNV Pathogenic 44778 rs397516881 10:121436429-121436429 10:119676917-119676917
47 LMNA NM_170707.4(LMNA):c.607G>A (p.Glu203Lys) SNV Pathogenic 48070 rs61195471 1:156104287-156104287 1:156134496-156134496
48 LMNA NM_170707.4(LMNA):c.644T>C (p.Leu215Pro) SNV Pathogenic 65764 rs61295588 1:156104600-156104600 1:156134809-156134809
49 LMNA NM_170707.4(LMNA):c.673C>T (p.Arg225Ter) SNV Pathogenic 48074 rs60682848 1:156104629-156104629 1:156134838-156134838
50 DSP NM_004415.4(DSP):c.3474dup (p.Glu1159fs) Duplication Pathogenic 517147 rs727503000 6:7579896-7579897 6:7579663-7579664
Sources

Expression for Dilated Cardiomyopathy

About this section
Search GEO for disease gene expression data for Dilated Cardiomyopathy.
Sources

Pathways for Dilated Cardiomyopathy

About this section

Pathways related to Dilated Cardiomyopathy according to KEGG:

36
# Name Kegg Source Accession
1 Dilated cardiomyopathy hsa05414

Pathways related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cardiac conduction 65
Show member pathways
 12.54 TPM1 TNNT2 TNNI3 SCN5A MYH6 MYBPC3
2
cGMP-PKG signaling pathway 36
Show member pathways
 12.41 TPM1 TNNT2 TNNI3 SCN5A MYH7 MYH6
3
Cytoskeletal Signaling 4
12.33 TPM1 TNNT2 TNNI3 LMNA FLNC DES
4
Arrhythmogenic right ventricular cardiomyopathy 36 1
11.99 LMNA DSP DMD DES ACTN2
5
Dilated cardiomyopathy 36
Show member pathways
 11.88 TPM1 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
6
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.63 TNNT2 TNNI3 DES
7
Cardiac muscle contraction 36
11.59 TPM1 TNNT2 TNNI3 MYH7 MYH6
8
Antiarrhythmic Pathway, Pharmacodynamics 60
11.38 SCN5A LMNA DSP
9
Cardiac Progenitor Differentiation 1
11.35 TNNT2 TNNI3 SCN5A MYH6
10
Striated Muscle Contraction 65 1
11.08 TPM1 TNNT2 TNNI3 MYH6 MYBPC3 DMD
Sources

GO Terms for Dilated Cardiomyopathy

About this section

Cellular components related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.37 TPM1 TNNI3 TAZ SCN5A PPP1R13L MYH7
2 cytosol GO:0005829 10.35 TPM1 TNNT2 TNNI3 PPP1R13L MYH6 MYBPC3
3 cytoskeleton GO:0005856 10.05 TPM1 FLNC DSP DMD DES CSRP3
4 sarcolemma GO:0042383 9.71 SCN5A FLNC DMD DES
5 myofibril GO:0030016 9.65 TNNT2 TNNI3 MYH7 MYH6 DMD
6 intercalated disc GO:0014704 9.63 SCN5A DSP DES
7 stress fiber GO:0001725 9.62 TPM1 MYH7 MYH6 BAG3
8 Z disc GO:0030018 9.61 SCN5A MYH7 MYH6 FLNC DMD DES
9 costamere GO:0043034 9.56 FLNC DMD
10 contractile fiber GO:0043292 9.55 TNNI3 DES
11 muscle myosin complex GO:0005859 9.54 MYH7 MYH6
12 myosin filament GO:0032982 9.54 MYH7 MYH6 MYBPC3
13 fascia adherens GO:0005916 9.49 DSP DES
14 troponin complex GO:0005861 9.48 TNNT2 TNNI3
15 cardiac myofibril GO:0097512 9.46 TNNT2 TNNI3 MYBPC3 DES
16 cardiac Troponin complex GO:1990584 9.43 TNNT2 TNNI3
17 sarcomere GO:0030017 9.23 TPM1 TNNT2 TNNI3 MYH7 MYH6 MYBPC3

Biological processes related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.85 TNNI3 TAZ RBM20 CSRP3
2 muscle organ development GO:0007517 9.77 LMNA DMD CSRP3
3 muscle contraction GO:0006936 9.76 TPM1 TNNT2 TNNI3 TAZ MYH7 MYH6
4 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.73 TPM1 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
5 sarcomere organization GO:0045214 9.72 TPM1 TNNT2 MYH6 CSRP3 ACTN2
6 regulation of heart contraction GO:0008016 9.71 TPM1 TNNT2 MYH6 DES
7 skeletal muscle tissue development GO:0007519 9.7 TAZ DMD CSRP3
8 positive regulation of ATPase activity GO:0032781 9.69 TPM1 TNNT2 MYBPC3
9 muscle cell cellular homeostasis GO:0046716 9.67 LAMP2 DMD BAG3
10 regulation of heart rate GO:0002027 9.67 SCN5A MYH7 MYH6 DMD
11 regulation of the force of heart contraction GO:0002026 9.65 MYH7 MYH6 CSRP3
12 regulation of muscle contraction GO:0006937 9.63 TPM1 TNNT2 TNNI3
13 intermediate filament organization GO:0045109 9.61 DSP DES
14 striated muscle contraction GO:0006941 9.61 TNNI3 MYH7 MYH6
15 muscle filament sliding GO:0030049 9.61 TPM1 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
16 muscle fiber development GO:0048747 9.59 FLNC DMD
17 cardiac muscle hypertrophy in response to stress GO:0014898 9.58 MYH7 MYH6
18 adult heart development GO:0007512 9.58 MYH7 MYH6
19 negative regulation of ATPase activity GO:0032780 9.57 TNNT2 TNNI3
20 response to denervation involved in regulation of muscle adaptation GO:0014894 9.56 SCN5A DMD
21 chaperone-mediated autophagy GO:0061684 9.54 LAMP2 BAG3
22 cardiac muscle contraction GO:0060048 9.36 TPM1 TNNT2 TNNI3 TAZ SCN5A PPP1R13L

Molecular functions related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.41 TPM1 TNNT2 TNNI3 TAZ SCN5A RBM20
2 identical protein binding GO:0042802 10.02 TPM1 TNNT2 PPP1R13L MYBPC3 LMNA FLNC
3 protein domain specific binding GO:0019904 9.76 TNNI3 SCN5A LAMP2 ACTN2
4 actin filament binding GO:0051015 9.63 TPM1 TNNI3 MYH7 MYH6 DMD ACTN2
5 structural constituent of cytoskeleton GO:0005200 9.62 TPM1 DSP DMD DES
6 cytoskeletal protein binding GO:0008092 9.56 TPM1 FLNC DES ACTN2
7 ankyrin binding GO:0030506 9.51 SCN5A FLNC
8 nitric-oxide synthase binding GO:0050998 9.49 SCN5A DMD
9 titin binding GO:0031432 9.48 MYBPC3 ACTN2
10 troponin C binding GO:0030172 9.4 TNNT2 TNNI3
11 structural constituent of muscle GO:0008307 9.35 TPM1 MYBPC3 DMD CSRP3 ACTN2
12 actin binding GO:0003779 9.32 TPM1 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
Sources

Sources for Dilated Cardiomyopathy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....